Advances in immunotherapy for triple-negative breast cancer.

Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, Zhang Z, Qiu P, Gu X. · 2023

Read Advances in immunotherapy for triple-negative breast cancer. by Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, Zhang Z, Qiu P, Gu X. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10474743.txt.

Introduction

Liu and co-authors reviewed immune therapy for triple-negative breast cancer in 2023. This cancer form lacks the three marks that guide most breast cancer drugs. Immune therapy trains the body's own defences to kill tumour cells. It can boost a tumour's visibility to immune cells and lift signals that shield it.

Checkpoint drugs lead the field, Liu reports. They block brakes on immune cells, and gene tests now help match them to subtypes. Trials pair these drugs with chemo, radiation, and targeted drugs. Newer partners include nano carriers, RNA vaccines, and gene therapy. The review asks why some tumours resist immune attack. It maps paths to beat that resistance in future care.

Catalog record

CREATORLiu Y, Hu Y, Xue J, Li J, Yi J, Bu J, Zhang Z, Qiu P, Gu X.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE126 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10474743

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Advances in immunotherapy for triple-negative breast cancer By Yang Liu, Yueting Hu, Jinqi Xue, Jingying Li, Jiang Yi, Jiawen Bu, Zhenyong Zhang, Peng Qiu, Xi Gu Published in: Molecular Cancer DOI: 10.1186/s12943-023-01850-7 ABSTRACT Abstract Background Immunotherapy has recently emerged as a treatment strategy which stimulates the human immune system to kill tumor cells. Tumor immunotherapy is based on immune editing, which enhances the antigenicity of tumor cells and increases the tumoricidal effect of immune cells. It also suppresses immunosuppressive molecules, activates or restores immune system function, enhances anti-tumor immune responses, and inhibits the growth f tumor cell. This offers the possibility of reducing mortality in triple-negative breast cancer (TNBC). Main body Immunotherapy approaches for TNBC have been diversified in recent years, with breakthroughs in the treatment of this entity. Research on immune checkpoint inhibitors (ICIs) has made it possible to identify different molecular subtypes and formulate individualized immunotherapy schedules. This review highlights the unique tumor microenvironment of TNBC and integrates and analyzes the advances in ICI therapy. It also discusses strategies for the combination of ICIs with chemotherapy, radiation therapy, targeted therapy, and emerging treatment methods such as nanotechnology, ribonucleic acid vaccines, and gene therapy. Currently, numerous ongoing or completed clinical trials are exploring the utilization of immunotherapy in conjunction with existing treatment modalities for TNBC. The objective of these investigations is to assess the effectiveness of various combined immunotherapy approaches and determine the most effective treatment regimens for patients with TNBC. Conclusion This review provides insights into the approaches used to overcome drug resistance in immunotherapy, and explores the directions of immunotherapy development in the treatment of TNBC. Keywords: Triple-negative breast cancer, Immunotherapy, Immune checkpoint, Drug resistance, Tumor microenvironment INTRODUCTION Breast cancer has become the commonest malignancy among women all over the world, and is related to the highest mortality rates from the disease. Triple-negative breast cancer (TNBC) is an entity that tests negative for the expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her-2), it is characterized by low differentiation, high invasiveness, a propensity for local and distant metastases, poor prognosis, and high recurrence rates [1]. Gene expression analysis shows that immune markers, mesenchymal phenotypes, androgen receptors, stem cell markers and basic markers are all associated with TNBC [2]. Based on findings from transcriptome research, TNBC may be divided into six subtypes, namely, basal-like 1, basal-like 2, mesenchymal stem cell, immunomodulatory, mesenchymal, and luminal androgen receptor [3]. In addition to the extracellular matrix (ECM), numerous immune cells in the tumor microenvironment (TME), including tumor-infiltrating lymphocytes (TILs), antigen-presenting cells, and fibroblasts contribute to the progression and metastasis in TNBC. At present, immunotherapy has become a new choice for many refractory solid tumors. Immune checkpoint inhibitors (ICIs) include inhibitors of programmed death receptor-1 (PD-1), programmed death receptor-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), which is the most well-known immunotherapeutic agents. Breast cancer has long been considered a “cold” tumor due to its limited T-cell infiltration and low tumor mutation burden. Nevertheless, TNBC exhibits a greater presence of infiltrating lymphocytes, thereby establishing a favorable immune microenvironment for the potential utilization of ICIs. TNBC also demonstrates a relatively substantial tumor mutation load, thereby offering an antigenic foundation for immune cell recognition. The expression of PD-L1 is notably elevated in TNBC, thereby presenting a promising target for the implementation of ICIs [4]. Immunotherapy holds significant clinical relevance for TNBC, as the combination of ICIs with chemotherapy has yielded promising therapeutic outcomes in TNBC patients. Subsequent investigations should be conducted to elucidate efficacious immunotherapy regimens, thereby offering novel approaches to enhance the therapeutic efficacy of TNBC. TME AND THERAPEUTIC RESISTANCE IN TNBC The tumor microenvironment (TME) encompasses tumor cells, cancer-associated fibroblasts (CAFs), immune cells including B and T lymphocytes, natural killer (NK) cells, tumor-associated macrophages (TAMs), the vasculature, and extracellular components including ECM, cytokines, chemokines, metabolites, and exosomes. The heterogeneity of TME within different subtypes of TNBC is notably pronounced [5]. The constituents of TME possess the ability to interact with one another, thereby altering the internal environment of the tumor and ultimately facilitating the development of resistance in TNBC. Research has indicated that non-cancerous cells within the TME play an important part in the development of cancer by facilitating tumor survival, progression, metastasis, and therapeutic resistance. The interaction between tumor cells and stromal cells in the TME, which are also implicated in tumor growth and drug resistance [2]. In addition, the proliferation, the metabolic remodeling, and the inhibition of cell apoptosis in tumor cells of TNBC can lead to hypoxia, acidosis, and oxidative stress within TME [6, 7]. Hypoxia, along with oxidative stress and acidosis, can induce the activation of lysyl oxidase (LOX) and subsequently reshape the ECM, and ultimately leading to the formation of chemotherapy resistance [8]. The activation of the collagen prolyl 4-hydroxylase P4H-α1/HIF-1 axis has been found to enhance the stemness of TNBC cells, resulting in a reduction in oxidative phosphorylation (OXPHOS) and reactive oxygen species (ROS) levels [9]. CAFs play a crucial role in promoting cancer progression and resistance to treatment through the secretion of cytokines, chemokines and ECM remodeling factors [10, 11]. Furthermore, CAF-induced lipid-associated macrophages (LAM) have been identified as mediators of immune suppression in breast cancer, particularly in TNBC [12]. The presence of ACSL3 in TNBC has been observed to result in the protection of TNBC cells from ferroptosis induced by mammary adipocytes [13]. Qiong et al. discovered that M2 macrophages secrete VEGF and activate PCAT6, thereby promoting the growth and metastasis of the cancer cells through the modulation of VEFGR2 in TNBC [14]. Zhang et al. have divided TNBC into macrophage-enriched subtype (MES) and neutrophil-enriched subtype (NES), revealing distinct mechanisms of immunotherapy resistance among different myeloid cell subtypes of TNBC [15]. The interactions between components of TME induce therapeutic resistance in TNBC are shown in Fig. 1. [Figure: Interactions between components of TME induce therapeutic resistance in TNBC. The hypoxia of TME induces the activation of LOX and reshapes the ECM, leading to the formation of chemotherapy resistance. The activation of the P4H-α1/HIF-1 axis has been found to enhance the stemness of TNBC cells, resulting in a reduction in OXPHOS and ROS. CAF-induced lipid-associated macrophages induce immunosuppression of TNBC. The adipocytes induce the production of oleic acid to result in the protection of TNBC cells from ferroptosis by ACSL3. The M2 macrophages secrete VEGF and activate PCAT6 to promote the proliferation and metastasis of tumor cells through the modulation of VEFGR2] REMODELING OF THE TME Abnormalities in the TME act as barriers to drug delivery, and are the main reasons for poor efficacy of chemotherapy and immunotherapy [16]. TNBC tissue exhibits severe fibrosis and abundant ECM deposition, which induces tumor vascular compression and reduces perfusion, which leads to poor drug delivery [17]. The Cytokines secreted by cancer-associated fibroblasts (CAFs) cause immunosuppression, tumor cell proliferation, epigenetic changes and ECM [18]. As TILs in the TME are closely related to the prognosis of TNBC, TME remodeling (recruiting CD4 + T cells, CD8 + T cells, and NK cells) improves the effect of immunotherapy which is a crucial approach used for treating breast cancer. The targets for reshaping the TME are therefore important for the treatment and prognosis

Read the complete text